Skip to main content

Table 8 Base case analysis results

From: Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

  Glargine NPH Incremental
Mean (SD) CI (low–high) Mean (SD) CI (low–high) Mean CI (low–high)
LE (years) 13.522 (0.165) 13.512–13.532 13.512 (0.16) 13.502–13.522 0.01 − 0.004 to 0.024
Undiscounted LE (years) 18.763 (0.28) 18.745–18.78 18.746 (0.271) 18.729–18.763 0.017
QALY 7.842 (0.105) 7.835–7.848 7.625 (0.104) 7.619–7.632 0.217 0.207–0.226
Undiscounted QALY (years) 10.651 (0.17) 10.641–10.662 10.347 (0.166) 10.337–10.357 0.304
Direct costs 701,015 (40,687) 698,493–703,536 678,641 (40,745) 676,115–681,166 22,373 18,726–26,021
Indirect costs 61,121 (6847) 60,697–61,546 62,135 (6637) 61,723–62,546 − 1013 − 1013 to − 1609
Combined costs 762,136 (47,535) 759,190–765,083 740,776 (47,382) 737,839–743,713 21,360 21,360–17,747
ICER      98,663 78,527–120,646
  1. Values are expressed as mean (standard deviation)
  2. HKD Hong Kong Dollar, ICER incremental cost-effectiveness ratio, LE life expectancy, LYG life year gained, QALY quality-adjusted life year